# Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

> **NCT06969170** · PHASE2 · RECRUITING · sponsor: **Queen's University** · enrollment: 50 (estimated)

## Conditions studied

- Generalized Anxiety Disorder (GAD)

## Interventions

- **DRUG:** Psilocybin (drug)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06969170
- **Lead sponsor:** Queen's University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-08-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06969170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06969170, "Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06969170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*